市場調查報告書

子宮癌治療及診斷市場:各癌症類型、治療方法、診斷法、地區(2017年∼2022年)

Global Uterine Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 353870
出版日期 內容資訊 英文 212 Pages
商品交期: 2-3個工作天內
價格
子宮癌治療及診斷市場:各癌症類型、治療方法、診斷法、地區(2017年∼2022年) Global Uterine Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography (2017 - 2022)
出版日期: 2017年01月24日內容資訊: 英文 212 Pages
簡介

全球子宮癌治療及診斷市場,預計從2015年的195億美元,以2∼6%的年複合成長率緩慢地成長。

本報告提供全球子宮癌治療及診斷市場相關調查,市場概要,各癌症類型、治療方法、診斷法、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 市場定義
  • 調查方法

第2章 摘要整理

第3章 市場概要

  • 市場成長要素
    • 對子宮疾病和可利用的治療方法的認識高漲
    • 醫療費用支出增加
    • 開發藥劑中創新與之後的技術進步
  • 市場阻礙因素
    • 癌症臨床實驗藥的成功概率低
    • 治療相關的高成本
    • 治療的副作用及高毒性
  • 市場機會
  • 市場威脅

第4章 波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係

第5章 市場區隔

  • 各癌症類型
    • 子宮肉瘤
    • 子宮內膜癌
  • 各治療法
    • 手術
    • 免疫療法
    • 放射線治療
    • 化療
    • 後續觀察
  • 各診斷法
    • 切片檢查
    • 超音波檢驗
    • 子宮鏡檢查
    • 子宮內膜刮宮術
    • 電腦斷層掃描
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲

第6章 競爭情形

  • 合併、收購
  • 協定、合作、夥伴關係
  • 新產品的銷售
  • 新加入企業的建議

第7章 企業簡介

  • Ariad Pharmaceuticals, Inc.
  • Abbott Laboratories
  • Becton, Dickinson & Co.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Siemens Healthcare Inc
  • Roche Ltd

第8章 附錄

  • 簡稱
  • 參考資料
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. According to the American Cancer Society, around 47,130 new cases of endometrial cancer were diagnosed, and 8,010 women died from it in 2012.

The Global Uterine Cancer Market is expected to grow modestly from USD 19,500 million in 2015, at a CAGR of 2-6%.

The global uterine cancer therapeutics & diagnostic market is segmented based on:

Type

Uterine sarcomas

Endometrial carcinomas (Has various sub-types)

Treatment

Surgery

Chemotherapy

Immunotherapy

Radiation therapy

Follow-up Treatment.

Furthermore, the diagnostics market is segmented under major tests such as:

Biopsy

Pelvic Ultrasound

Hysteroscopy

Dilation and curettage

CT Scan

Based on geography it is segmented as:

Asia-Pacific

North America

Europe

Latin America

According to the surveys by WHO, incidences of endometrial cancer is greater in the developed regions such as the North American countries followed by the European nations due to the shifting lifestyle of women. Pervasiveness of uterine cancer is more in women aged 50 years and above.

Some of the key participants in the industry include Ariad Pharmaceuticals, Inc., Abbott Laboratories, Becton, Dickinson & Co., Merck & Co., Inc., GlaxoSmithKline Plc, Novartis AG, Sanofi, Siemens Healthcare Inc., Roche Ltd etc.

Drivers:

Upsurge in awareness about uterine diseases

Available therapies in the market

Increasing health care expenditure

Increasing incidences of uterine cancer

Technological developments & drug innovations with regard to uterine cancer

Advanced health care services

Restraints:

Low success rate in clinical trials for cancer drugs

High cost associated with the treatment

Adverse side-effects

High toxicity of drugs

SPECIALITIES OF THIS REPORT

The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

The report contains wide range of information about the leading market players and the major strategies adopted by them.

WHAT THE REPORT OFFERS

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

Table of Contents

1. Introduction

  • 1.1 Market Definition
  • 1.2 Research Methodology

2. Executive Summary

3. Market Overview

  • 3.1 Market Drivers
    • 3.1.1 Rise in awareness about Uterine diseases and their available therapies
    • 3.1.2 Increasing health care expenditure
    • 3.1.3 Innovation in drug development, and subsequent technological advancements
  • 3.2 Market Restraints
    • 3.2.1 Low success rate in clinical trails for cancer drugs
    • 3.2.2 High cost associated with the treatment
    • 3.2.3 Adverse side-effects of treatment and high toxicity of drugs
  • 3.3 Market Opportunitites
  • 3.4 Market Threats

4. Porters Five Force Analysis

  • 4.1 Bargaining Power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Degree of competition
  • 4.4 Threat of substitution
  • 4.5 Threat of new entrants

5. Market Segmentation

  • 5.1 Global Uterine Cancer Therapeutics & Diagnostic Market, by Cancer Type
    • 5.1.1 Uterine sarcomas
    • 5.1.2 Endometrial carcinomas
      • 5.1.2.1 Adenocarcinoma
      • 5.1.2.2 Carcinosarcoma
      • 5.1.2.3 Squamous cell carcinoma
      • 5.1.2.4 Others
  • 5.2 Global Uterine Cancer Therapeutics Market
    • 5.2.1 Surgery
    • 5.2.2 Immunotherapy
    • 5.2.3 Radiation therapy
    • 5.2.4 Chemotherapy
    • 5.2.5 Follow-up Treatment
  • 5.3 Global Uterine Cancer Diagnostics Market
    • 5.3.1 Biopsy
    • 5.3.2 Pelvic ultrasound.
    • 5.3.3 Hysteroscopy
    • 5.3.4 Dilation and curettage
    • 5.3.5 CT scan
  • 5.4 Global Uterine Cancer Therapeutics Market, By Region
    • 5.4.1 North America
      • 5.4.1.1 U.S.
      • 5.4.1.2 Canada
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 France
      • 5.4.2.3 Spain
      • 5.4.2.4 Italy
      • 5.4.2.5 U.K.
      • 5.4.2.6 Rest Of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 India
      • 5.4.3.3 Japan
    • 5.4.4 Latin America
    • 5.4.5 Middle East & Africa

6. Competitive Landscape

  • 6.1 Mergers & Acquisitions
  • 6.2 Agreements, Collaborations & Partnerships
  • 6.3 New Product Launches
  • 6.4 Recommendations to new market players

7. Company Profiles

  • 7.1 Ariad Pharmaceuticals, Inc.
  • 7.2 Abbott Laboratories
  • 7.3 Becton, Dickinson & Co.
  • 7.4 GlaxoSmithKline Plc
  • 7.5 Merck & Co., Inc.
  • 7.6 Novartis AG
  • 7.7 Sanofi
  • 7.8 Siemens Healthcare Inc
  • 7.9 Roche Ltd

8. Appendix

  • 8.1. Abbreviations
  • 8.2. Sources
  • 8.3. Bibliography
  • 8.4. Disclaimer